Histoplasmosis is a fungal disease caused by infection with Histoplasma capsulatum. Histoplasmosis, which can be acquired from soil contaminated with bird or bat droppings, occurs worldwide and is one of the most common pulmonary and systemic mycoses in the United States (1) . However, among international travelers returning from areas in which histoplasmosis is endemic, histoplasmosis is rare, accounting for <0.5% of all diseases diagnosed in this group (1, 2) . During FebruaryMarch 2008, the Pennsylvania and Virginia departments of health investigated a cluster of respiratory illness among three mission groups that had traveled separately to El Salvador to renovate a church. This report summarizes the results of the investigation. Of 33 travelers in the three mission groups for whom information was available, 20 (61%) met the case definition for histoplasmosis. Persons who reported sweeping and cleaning outdoors (relative risk [RR] = 2.1, 95% confidence interval [CI] = 1.3-3.6), digging (RR = 2.6, CI = 1.1-6.1), or working in a bird or bat roosting area (RR = 1.8, CI = 1.3-2.4) had a greater risk for illness. The findings emphasize the need for travelers and persons involved in construction activities to use personal protective equipment and decrease dust-generation when working in areas where histoplasmosis is endemic. Clinicians should consider histoplasmosis as a possible cause of acute respiratory or influenza-like illness in travelers returning from areas in which histoplasmosis is endemic.
On February 13, 2008, the Pennsylvania Department of Health (PADOH) notified the Virginia Department of Health (VDH) of a cluster of nine persons with respiratory illness. The nine persons were among 11 members of a Pennsylvania-based mission group who had been renovating a church in Nueva San Salvador, El Salvador, during January 20-27, 2008. Two other mission groups, one from Virginia (16 members) and one from Pennsylvania (eight members), had traveled separately to assist with renovations of the same church during January [3] [4] [5] [6] [7] [8] [9] [10] 2008 and February 2-10, 2008, respectively. After arrival, mission members immediately began renovation activities at the church. Renovation projects varied among the mission groups and included cleaning of indoor and outdoor renovation sites, electrical and plumbing installation, construction of additional rooms, roof replacement, and septic tank excavation. Mission members remained in El Salvador for the entire trip, but also visited local markets and churches and took a 1-day trip to either a beach or lake.
The initial report from PADOH indicated that all nine persons from the initial cluster, upon returning from El Salvador, had presented to their health-care providers with respiratory symptoms. One of these persons was diagnosed with suspected histoplasmosis based on physical exam and a chest radiograph. To search for additional cases of illness among the mission groups, PADOH and VDH contacted the trip organizers and leaders.
A case of histoplasmosis was defined as 1) a laboratoryconfirmed H. capsulatum infection or 2) self-reported fever and two additional symptoms (i.e., headache, cough, chest pain, or difficulty breathing) beginning at least 24 hours after arrival in El Salvador, in any mission group member who traveled to El Salvador during January 3-February 10, 2008. Laboratoryconfirmation was defined as either a urine or serum Histoplasma antigen enzyme immunoassay (EIA) test result of ≥0.6 ng/mL.
All participants from each mission group were administered a standard questionnaire through their church pastors or through telephone interviews. Information collected included demographics, illness, underlying health conditions, protective measures used, and potential exposures. Medical records of hospitalized patients also were reviewed, and a retrospective cohort study of the mission members was conducted.
Statistical differences between proportions were assessed using chi-square and Fisher's exact tests of significance, when appropriate. Mean ages were compared using a t-test. Relative risk and 95% confidence interval estimates were calculated using Poisson regression analysis with robust variance.
Information was collected from 33 (94%) of the 35 mission group participants. Twenty persons (12 males and eight females) met the case definition for histoplasmosis, for an overall attack rate of 61%. The 20 cases included histoplasmosis in five (36%) of 14 persons from the Virginia mission group, nine (82%) of 11 persons from the first Pennsylvania mission group, and six (75%) of eight persons from the second Pennsylvania mission group (Figure) . Seven (35%) of the 20 ill persons met the case definition through laboratory-confirmed histoplasmosis based on urine specimens tested by EIA. The other 13 (65%) ill persons met the case definition through the symptom criteria, but eight of these 13 persons had urine specimens that tested negative by EIA. No participants had paired serologic antibody test results available. Median time from symptom onset to specimen collection date was 6 days (range: 1-28 days).
Incubation periods could not be calculated because exact dates of exposure were not available; however, the median number of days between arriving in El Salvador and onset of symptoms was 12 (range: 3-25 days). Primary symptoms reported among the 20 ill persons meeting the case definition included fatigue (100%), fever or chills (95%), and headache (95%) ( Table 1) . Nineteen (95%) of the 20 ill persons visited a health-care provider, and six (30%) required hospitalization for their illness; all subsequently recovered. Because the clinical manifestation of histoplasmosis partly depends on the underlying health and immune status of the host, mission members were asked about their underlying medical conditions. Three ill persons reported a history of cancer, none reported a history of chronic lung disease, and none were current smokers.
Differences in age (p=0.13), sex (p=0.44), and membership in mission group (p=0.06) were not statistically significant. Digging (RR = 2.6), sweeping or cleaning outdoors (RR = 2.1), and septic tank excavation (RR = 1.7) were associated with increased risk for illness (Table 2) . For those persons who reported two or three high-risk exposures, defined as digging, sweeping indoors, or sweeping outdoors, the relative risk for illness was elevated (RR = 2.6), compared with those with previous research and revealed that performing outdoor activities, particularly those that cause soil disruption and spore aerosolization, increased the risk for acquiring histoplasmosis. Specifically, the two activities with the highest relative risk for illness were digging and sweeping outdoors.
Histoplasmosis infections typically are asymptomatic or cause mild symptoms from which persons recover without antifungal or other treatment; persons with more severe forms of the infection (i.e., acute pulmonary, chronic pulmonary, and progressive disseminated histoplasmosis) are recommended for treatment with antifungal agents, such as amphotericin B (7) . In this outbreak, the high overall attack rate among an otherwise healthy cohort, along with illness severe enough to require health-care services (including hospitalization), suggests substantial exposure to fungal spores during the renovation activities. In addition, working in an environment harboring bird or bat excrement likely increased the risk for acquiring histoplasmosis.
Ultimately, the cause of this outbreak might be that the volunteers were not aware of the risk for histoplasmosis and therefore took no precautions, such as using personal protective equipment or taking care to decrease dust generation when working in this area of endemic disease. Although persons living or working in areas of endemic histoplasmosis might have previous health education and training about the risk and prevention of this disease, volunteers who travel to and work in these areas are likely to have limited, if any, training on disease risk and prevention.
Multiple laboratory tests, including culture, histopathology, serology, and EIA antigen tests, can be used to diagnose histoplasmosis. The sensitivity and specificity of these tests depend on factors that include the patient's clinical syndrome, type and 
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timing of specimen collection, fungal burden, and the host's immune status (8) . In general, testing of convalescent serum samples offers the highest sensitivity for subacute and chronic pulmonary disease, and antigen testing (i.e., a quantitative, second-generation EIA), appears to be one of the most sensitive tests for acute pulmonary histoplasmosis (8) . However, the EIA antigen test is less sensitive in milder infections when the fungal burden is lower (8, 9) . In this outbreak, five of seven patients with a positive urine EIA test required hospitalization. The findings in this report are subject to at least three limitations. First, information about exposures and illness were ascertained via self-report, which might be associated with recall bias and subsequent exposure and disease misclassification. Second, misclassification of disease status is possible, given the negative antigen test results and given that infection with other respiratory pathogens (e.g., influenza virus) could not be ruled out for all ill persons. Finally, the majority of diagnostic specimens were tested by Histoplasma EIA only. Because EIA test sensitivity increases with increasing illness severity (8, 9) , specimens collected from persons with less severe disease might have tested falsely negative.
Persons in areas of endemic histoplasmosis who perform certain jobs or activities, such as construction and farming, are at risk for acquiring histoplasmosis (10) . Travel clinics and organizers of group travel to areas of endemic histoplasmosis should be informed about the risk for histoplasmosis among travelers with potential exposure to H. capsulatum. Clinicians should consider a diagnosis of histoplasmosis when evaluating a patient who has acute febrile respiratory illness and has traveled to an area in which histoplasmosis is endemic.
Clinicians also should inquire about the patient's activities in the area of endemic disease. If histoplasmosis is suspected, consultation with laboratory experts is recommended to ensure the proper collection and referral of blood and urine specimens. Depending on the patient's clinical presentation, antigen testing for Histoplasma, convalescent serologic testing to detect antibodies, or culture might be performed to diagnose histoplasmosis. Travelers to areas of endemic histoplasmosis who visit caves or areas with high concentrations of bird or bat excrement, or who perform dust-generating activities, should consider using personal protective equipment (e.g., respirators) and dust-suppression strategies (e.g., keeping surfaces wet) to reduce their potential exposure to H. capsulatum. Antimicrobial susceptibility breakpoints are established based on 1) the pharmacokinetic and pharmacodynamic properties of an antimicrobial agent and 2) data correlating individual MIC results with patient outcomes. Under the former criteria, susceptible, intermediate, and resistant MIC breakpoints for penicillin were <0.06, 0.12-1, and >2 µg/mL, respectively, for all pneumococcal isolates, regardless of clinical syndrome or route of penicillin administration. Those breakpoints remain unchanged for patients without meningitis who can be treated with oral penicillin (e.g., for outpatient pneumonia). However, for patients without meningitis who are treated with intravenous penicillin, the new breakpoints are <2, 4, and >8 µg/mL, respectively. In addition, isolates from patients with meningitis are now categorized as either susceptible or resistant, with intravenous penicillin breakpoints of <0.06 or >0.12 µg/mL, respectively (Table) . Because the blood-brain barrier limits penetration of penicillin into the cerebrospinal fluid (CSF), no intermediate category for meningitis exists.
To conduct this analysis, cases of IPD were identified through ABCs. Cases of IPD were defined by isolation of S. pneumoniae from a normally sterile site, such as blood or CSF. S. pneumoniae infections in persons with noninvasive isolates (e.g., from sputum) were not considered IPD cases. Cases were categorized as meningitis or nonmeningitis based on medical record review (e.g., clinical presentation) and source of the isolate. If a case was classified as meningitis on the basis of the patient's clinical presentation but pneumococcus was isolated from blood rather than CSF, the new meningitis breakpoints were applied to the blood isolate (1). Isolates were tested for susceptibility at reference laboratories, using CLSI methods (1) . Because 88% of persons with nonmeningitis IPD are hospitalized and oral penicillin is not used for treatment of hospitalized persons with IPD, the oral penicillin route was not considered in this analysis, and only the new intravenous penicillin breakpoints were applied to the MICs.
During 
under the former breakpoints to 5,989 (93.2%) using the new breakpoints for intravenous treatment ( Figure 1 ). The number of isolates associated with nonmeningitis syndromes with intermediate susceptibility to penicillin decreased from 962 (15.0%) under the former breakpoints to 357 (5.6%) under the new intravenous breakpoints; the number of penicillin-resistant isolates decreased from 664 (10.3%) under the former breakpoints to 77 (1.2%) under the new intravenous breakpoints. The number of penicillin-susceptible isolates associated with meningitis remained unchanged at 306 (73%). All isolates associated with meningitis that had been categorized under the former breakpoints as having intermediate susceptibility to penicillin were recategorized as penicillin resistant under the new breakpoints, increasing the number of resistant isolates from 45 (10.7%) to 116 (27.5%) ( Figure 2 Editorial Note: The new susceptibility breakpoints for S. pneumoniae, published by CLSI in January 2008, were the result of a reevaluation that showed clinical response to penicillin was being preserved in clinical studies of pneumococcal infection, despite reduced susceptibility response in vitro. CLSI took a similar approach in 2003, when third-generation cephalosporin breakpoints for S. pneumoniae were redefined for isolates from patients with and without meningitis (2). The former penicillin breakpoints for S. pneumoniae were based on attainable concentrations of penicillin in CSF and the MIC at which meningitis treatment was thought to fail. However, published studies evaluating penicillin as monotherapy for treatment during the first 48 hours of nonmeningitis pneumococcal infections have not shown increased case-fatality rates associated with penicillin MICs <2 µg/mL (3) (4) (5) . These studies provide evidence that that the former CLSI breakpoints for penicillin underestimated the clinical utility of that agent for intravenous therapy of nonmeningitis pneumococcal infections.
Because most antimicrobial reports from clinical laboratories have included only one set of susceptibility breakpoints, the use of multiple sets of breakpoints has the potential to cause confusion among clinicians. Some patients with clinical signs and symptoms of pneumococcal meningitis have negative cultures from CSF but positive cultures from blood. Therefore, CLSI recommends that both sets of breakpoints for intravenous therapy (i.e., for meningitis and nonmeningitis syndromes) be reported for all pneumococcal isolates not collected from CSF (1). Professional society guidelines state that, after patients have received empiric therapy and culture and susceptibility results are available, penicillin should be used to treat infections caused by penicillin-susceptible S. pneumoniae (6) . Clinicians should review all susceptibility results, decide which set of breakpoints to use, based on the patient's clinical presentation and the planned route of drug administration, and then decide whether penicillin or some other antimicrobial is most appropriate for treatment. If a third-generation cephalosporin is considered as an alternative for treatment, clinicians also should evaluate both susceptibility breakpoints provided for third-generation cephalosporins (2) . Clinical laboratory reports should include sufficient information regarding the susceptibility results, so that clinicians can apply the appropriate breakpoints to their patients.
Use of narrow-spectrum agents, such as penicillin, is encouraged to prevent the spread of antimicrobial-resistant S. pneumoniae and also the spread of methicillin-resistant Staphylococcus aureus and Clostridium difficile, which can result from use of broader-spectrum antimicrobials (7, 8) . The changes in penicillin breakpoints for S. pneumoniae have the potential to allow clinicians to increase use of penicillin to treat penicillin-susceptible nonmeningitis pneumococcal infections, instead of using broader-spectrum antimicrobials.
Some state and local health departments conduct surveillance for antimicrobial-resistant pneumococcal infections. Because of the breakpoint changes described in this report, those health departments might observe decreases in reported cases of antimicrobial-resistant IPD during 2008. Health departments should take these breakpoint changes into consideration when interpreting trends in antimicrobial resistance.
Brief Report

Respiratory Syncytial Virus Activity -United States, July 2007-December 2008
Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in children aged <1 year and is a major cause of respiratory illness in older adults (1, 2) . RSV is transmitted person-to-person via close contact, droplets, and fomites. Each year in the United States, an estimated 75,000-125,000 children aged <1 year are hospitalized with RSV (1). Those at increased risk for hospitalization include premature infants meeting certain criteria and persons of any age with compromised respiratory, cardiac, and immune systems (3, 4) . RSV incidence follows a seasonal pattern. In temperate climates, the RSV season generally occurs during the fall, winter, and spring months. However, the timing of RSV Data are presented for each of the 10 HHS regions, allowing greater characterization of geographic variability in RSV detections than the four U.S. Census regions used in previous MMWR reports (6); the findings can be used to determine the optimal timing of RSV prophylaxis for infants and children at high risk in each region. The HHS regions (listed by region number and headquarter city) include Region 1 (Boston), Region 2 (New York), Region 3 (Philadelphia), Region 4 (Atlanta), Region 5 (Chicago), Region 6 (Dallas), Region 7 (Kansas City), Region 8 (Denver), Region 9 (San Francisco), and Region 10 (Seattle). Florida is summarized separately because, historically, the RSV season in Florida has been distinct from the remainder of Region 4 (Atlanta) (6) ( Table  and Figure The season onset date for all 10 HHS regions ranged from mid-October (week ending October 13, 2007) to mid-December (week ending December 15, 2007); however, in Florida, the season onset occurred in early July (week ending July 7, 2007) . After Florida, the RSV season began the earliest in Region 6 (Dallas) and Region 2 (New York) (mid-October), followed by Region 4 (Atlanta) (late October). The RSV season started in Region 3 (Philadelphia) in early November, followed by Region 5 (Chicago) in mid-November, and Region 7 (Kansas City) and Region 9 (San Francisco) in late November. The RSV season began in Region 1 (Boston) and Region 10 (Seattle) in early December and started the latest in Region 8 (Denver) (mid December).
The season offset for all 10 HHS regions and Florida ranged from late January (week ending January 26, 2008) to mid-April (week ending April 12, 2008). The season offset occurred the earliest in Florida (late January), followed by Region 2 (New York) and Region 6 (Dallas) (early February), Region 1 (Boston) and Region 3 (Philadelphia) (mid-February), and Region 4 (Atlanta) (late February). The RSV season ended in Region 7 (Kansas City) in early March, followed by Region 8 (Denver) and Region 9 (San Francisco) in late March. The RSV season ended the latest in Region 5 (Chicago) (early April) and Region 10 (Seattle) (mid-April).
The median RSV season duration among the 10 HHS regions was 17 weeks (range: 12-21 weeks). The regions with the shortest seasons were Region 1 (Boston) (12 weeks), followed by Region 3 (Philadelphia) and Region 7 (Kansas City) (15 weeks). The regions with the longest seasons were Region 5 (Chicago) (21 weeks), followed by Region 9 (San Francisco) (19 weeks) and Region 10 (Seattle) (19 weeks). The season in Florida lasted 30 weeks. 
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